RNAC vs. SGMT, KPTI, VXRT, NGM, AMLX, SYRS, CRDL, PDSB, IMAB, and INCR
Should you be buying Cartesian Therapeutics stock or one of its competitors? The main competitors of Cartesian Therapeutics include Sagimet Biosciences (SGMT), Karyopharm Therapeutics (KPTI), Vaxart (VXRT), NGM Biopharmaceuticals (NGM), Amylyx Pharmaceuticals (AMLX), Syros Pharmaceuticals (SYRS), Cardiol Therapeutics (CRDL), PDS Biotechnology (PDSB), I-Mab (IMAB), and InterCure (INCR). These companies are all part of the "medical" sector.
Sagimet Biosciences (NASDAQ:SGMT) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, community ranking, dividends and institutional ownership.
Sagimet Biosciences received 5 more outperform votes than Cartesian Therapeutics when rated by MarketBeat users.
87.9% of Sagimet Biosciences shares are owned by institutional investors. Comparatively, 86.9% of Cartesian Therapeutics shares are owned by institutional investors. 17.6% of Sagimet Biosciences shares are owned by company insiders. Comparatively, 31.2% of Cartesian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Sagimet Biosciences has a net margin of 0.00% compared to Sagimet Biosciences' net margin of -845.01%. Cartesian Therapeutics' return on equity of 0.00% beat Sagimet Biosciences' return on equity.
Sagimet Biosciences has higher earnings, but lower revenue than Cartesian Therapeutics.
Sagimet Biosciences presently has a consensus target price of $39.60, indicating a potential upside of 774.17%. Cartesian Therapeutics has a consensus target price of $45.00, indicating a potential upside of 91.90%. Given Cartesian Therapeutics' higher possible upside, equities analysts plainly believe Sagimet Biosciences is more favorable than Cartesian Therapeutics.
In the previous week, Sagimet Biosciences had 1 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 10 mentions for Sagimet Biosciences and 9 mentions for Cartesian Therapeutics. Cartesian Therapeutics' average media sentiment score of 0.58 beat Sagimet Biosciences' score of -0.05 indicating that Sagimet Biosciences is being referred to more favorably in the media.
Summary
Sagimet Biosciences beats Cartesian Therapeutics on 11 of the 13 factors compared between the two stocks.
Get Cartesian Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RNAC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RNAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cartesian Therapeutics Competitors List
Related Companies and Tools
